Hypertension Types and Subtypes
Hypertension is the most prevalent CV disorder in the world and according to the WHO, it affects 1.28 billion adults aged 30–79 years worldwide, two-thirds living in low-income and middle-income countries. In 2019, the global age-standardised average prevalence of hypertension in adults aged 30–79 years was reported to be 34% in men and 32% in women.
Modern Medicine – Issue 4 2024
Resistant Hypertension-Updates, issues and approach to management
Successful management of poorly controlled hypertension requires careful distinction of true resistant hypertension from other causes such as poor adherence to hypertension medications, undiagnosed secondary hypertension and white-coat hypertension. An individualised approach that includes modifying lifestyle and diet and optimising pharmacotherapies is recommended for patients with suspected resistant hypertension.
Modern Medicine – Issue 2 2022
Hypertension in People with Diabetes Modern trends in management
The major cause of mortality in diabetes remains cardiovascular disease (CVD). Thus, any risk factors associated with CVD must be aggressively treated in patients with diabetes. Hypertension is one of these risk factors and should be appropriately managed in such individuals. The advent of new glucose lowering drugs such as sodium-glucose cotransporter
2 inhibitors may provide clinicians with additional opportunity to reduce BP.
Modern Medicine – Issue 6 2019
How to Diagnose and Manage Resistant Hypertension – MM1510
The number of truly drug-resistant hypertensive patients is small if careful attention is paid to blood pressure measurement , lifestyle measures are instituted and treatment is adjusted as required. An effective drug combination for the treatment of resistant hypertension is an ACE inhibitor (or angiotensin II receptor blocker), a calcium channel blocker and a thiazide-like diuretic, with possibly the addition of a fourth drug.
Modern Medicine – October 2015
Telmisartan More Than an Antihypertensive – MM1502
Telmisartan, a well established angiotensin type 1 receptor antagonist,
is indicated for the reduction of cardiovascular morbidity in patients with manifest atherothrombotic cardiovascular disease (CVD) or type 2 diabetes mellitus with documented target organ damage, as well as for the treatment of hypertension.
Modern Medicine – February 2015
Fibrate Therapy for Dyslipidaemia and Prevention of Cardiovascular Disease – MM1410
The main use of fibrates is for the treatment of dyslipidaemia to lower plasma triglyceride levels and to raise HDL-cholesterol (HDL-C) levels. The effects of fibrates on LDL-cholesterol levels vary. Fibrates may be used either as monotherapy or in combination with statins. When combined with statins, fenofibrate is the preferred fibrate as it has a low risk of myopathy. The benefits of fibrate therapy in preventing ischaemic cardiovascular disease events appear to be confined to patients with baseline dyslipidaemia (raised triglyceride levels and/or low HDL-C levels).
Modern Medicine – October 2014
Refractory Hypertension: Overcoming Hard to Control Blood Pressure – MM1407
Refractory hypertension must be differentiated carefully from hypertension caused by other treatable conditions or poor compliance.
Modern Medicine – July 2014
Game Changers in Type 2 Diabetes: After Three Antihypertensives, What’s Next? – MM1407
Hypertension is an important risk factor for both micro- and macrovascular complications in people with type 2 diabetes and can be difficult to control.
Modern Medicine – July 2014
